Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Alcohol Abuse, Alcohol Dependence, Heavy Drinking Days
Interventions: Kudzu extract, Placebo, Medical Management; Drug · Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Healthy Volunteers
Interventions: Soticlestat, Itraconazole, Mefenamic acid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Tinnitus
Interventions: Zinc, Placebo oral capsule; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prostate Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: IW-1973, Itraconazole; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Indigestion, Heartburn
Interventions: HLNatural, Inc. Upset Stomach Relief; Dietary Supplement
Lead sponsor: Hawthorne Effect Inc.; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Fibroids
Interventions: Proellex®; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more

Conditions: Hypertension
Interventions: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatitis C
Interventions: Daclatasvir, Darunavir, Ritonavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cocaine Dependence
Interventions: Clavulanic Acid Only Product, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Diabetic Peripheral Neuropathy
Interventions: Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 50
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more

Conditions: Depression, Bipolar
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 33 more

Conditions: Triple Negative Breast Cancer
Interventions: ENMD-2076; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: Pexacerfont, Escitalopram, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 45
States / cities: Springdale, Arkansas • Orange, California • Upland, California + 39 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir, placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 67
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more

Conditions: Healthy
Interventions: TP 3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Multiple Myeloma
Interventions: Ixazomib, Melphalan, Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Morgantown, West Virginia

Conditions: Pre-hypertension
Interventions: carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril, placebo and placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 19 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Tourette's Syndrome
Interventions: PF-03654746, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Solid Tumors
Interventions: Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Pseudoxanthoma Elasticum
Interventions: Magnesium Oxide, Placebo; Drug
Lead sponsor: Mark Lebwohl; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Nausea, Vomiting
Interventions: Ginger, Placebo Oral Tablet; Drug
Lead sponsor: Joel Yarmush; Other
Eligibility: 20 Years to 49 Years · Female only
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Brooklyn, New York

Search by objective public record fields.

Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons

A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Zinc to Treat Tinnitus in the Elderly

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers

Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Vascular Improvement With Olmesartan Medoxomil Study

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients